The FDA has approved Jascayd (nerandomilast) tablets to treat idiopathic pulmonary fibrosis, a rare, progressive lung disease that can cause scarring and breathing difficulties.
The approval marks the first new therapy for IPF approved in more than a decade. The drug’s efficacy was evaluated in two randomized, double-blind, placebo-controlled trials, wherein patients taking Jascayd experienced a significantly smaller decline in forced vital capacity compared with those receiving placebo, according to an Oct. 7 FDA bulletin.
The recommended dosage is 18 mg twice daily, roughly 12 hours apart. Dosage may be reduced to 9 mg twice daily for patients experiencing intolerability, excluding those on pirfenidone.
Common side effects observed in at least 5% of trial participants included diarrhea, COVID-19, upper respiratory tract infection, depression, weight loss, decreased appetite, nausea, fatigue, headache, vomiting, back pain and dizziness.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
